2022
COVID-19 Nasal Spray Vaccine
2020
IPO in Shanghai Stock Exchange. Stock Code SH.603392
2019
Innovax received New Drug Certificate for Cecolin® Recombinant HPV Vaccine. Urine HIV self-test launched in China.
2012
Hecolin® awarded the Most Innovative Asian Biotech Excellence Award at the 6th World Vaccine Congress Asia in Singapore
2011
Innovax received New Drug Certificate for Hecolin®
2011
The Phase III Clinical Trial Research Team working on the Hepatitis E vaccine was awarded “Excellent Team of National Science and Technology Program” in the 11th five-year plan period by the Ministry of Science and Technology, China
2011
Innovax set up a new department for the development of integrated diagnostic instruments and Point of Care Testing (POCT) devices and reagent kits
2011
Innovax obtained ‘Excellent Product’ Certificate at 13th China Hi-Tech Fair
2010
Innovax awarded 2nd Prize of National Award for Technological Invention
2010
Hepatitis E Vaccine Phase III study published in The Lancet and Hepatology
2008
Xiamen YST Bio-tech Co., Ltd. was formally merged with Beijing Wantai and renamed as Xiamen Innovax Biotech Co., Ltd.(lnnovax)
2006
China Torch Program supports recombinant Hepatitis E vaccine
2005
Xiamen YST Bio-tech Co., Ltd. was founded by YST with a focus on research and development/commercialization
2001
YST acquired Beijing Biological Pharmacy Enterprise Co., Ltd. (Wantai)
2000
YST invested in and set up Joint Bio Pharmacy R&D Center with Xiamen University
1991
Established Wantai Biopharm